Alastair Knight
Overview
Explore the profile of Alastair Knight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Michaelidou M, Whitten S, Bajaj P, Knight A, Spoudeas H
J Pediatr Endocrinol Metab
. 2019 Mar;
32(3):207-213.
PMID: 30844762
Background We previously reported improved persistence and adherence to daily recombinant growth hormone (rGH) in children using jet transjection delivery compared to using needle-based devices. This study examines the relationship...
3.
Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J
Int J Clin Pharmacol Ther
. 2017 Dec;
56(2):81-85.
PMID: 29231163
Objectives: To investigate plasma levels of buprenorphine and norbuprenorphine and their relationship to respiratory depression. Materials And Methods: Opioid-dependent subjects were randomized 2 : 1 to novel lyophilized rapid-disintegrating tablet...
4.
Strang J, Reed K, Bogdanowicz K, Bell J, van der Waal R, Keen J, et al.
Eur Addict Res
. 2017 Mar;
23(2):61-70.
PMID: 28268215
Aims: To test the safety of new buprenorphine oral lyophilisate wafer ("bup-lyo") versus standard sub-lingual buprenorphine ("bup-SL"). Design: Randomised (2:1) open-label study; opioid-dependent subjects; subsequent partial cross-over. Settings: Specialised clinical...
5.
Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, et al.
Int J Clin Pharmacol Ther
. 2016 Mar;
54(4):315-22.
PMID: 26952037
Objectives: To compare the single-dose pharmacokinetics (PK), safety, and immunogenicity of the biosimilar infliximab (BOW015) to reference infliximab (rIFX) in healthy volunteers and to establish bioequivalence. Methods: In this randomized,...
6.
Knight A, Haines J, Stals A, Li D, Uyttendaele M, Knight A, et al.
Int J Food Microbiol
. 2015 Sep;
216:40-9.
PMID: 26398283
Human noroviruses (hNoV) are the single largest cause of acute gastroenteritis in the western world. The efficacy of hNoV control measures remains largely unknown, partly owing to the inability to...
7.
Mann A, Noulin N, Catchpole A, Stittelaar K, De Waal L, Veldhuis Kroeze E, et al.
PLoS One
. 2014 May;
9(5):e93761.
PMID: 24850536
We investigated the protective efficacy of two intranasal chitosan (CSN and TM-CSN) adjuvanted H5N1 Influenza vaccines against highly pathogenic avian Influenza (HPAI) intratracheal and intranasal challenge in a ferret model....
8.
Perelman M, Knight A
Int J Clin Pharmacol Ther
. 2013 Oct;
51(12):942-7.
PMID: 24120713
Objective: Fentanyl pectin nasal spray (FPNS) is approved for management of breakthrough pain in cancer. It is available in 100 and 400 μg strength products which allow for doses of...
9.
Perelman M, Fisher A, Smith A, Knight A
Int J Clin Pharmacol Ther
. 2013 Mar;
51(5):349-56.
PMID: 23458227
Objectives: Fentanyl pectin nasal spray (FPNS, Lazanda® in the US and PecFent® in Europe and Australia) is a novel analgesic approved for the management of breakthrough pain in cancer patients....